Format

Send to:

Choose Destination
See comment in PubMed Commons below
Korean J Intern Med. 2009 Mar;24(1):48-54. doi: 10.3904/kjim.2009.24.1.43.

EGFR and KRAS mutations in patients with adenocarcinoma of the lung.

Author information

  • 1Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea. jangtw@ns.kosinmed.or.kr

Abstract

BACKGROUND/AIMS:

Mutations of the epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene (KRAS) are important in the pathogenesis of lung cancer, and recent reports have revealed racial and geographical differences in mutation expression.

METHODS:

This study was conducted to investigate the prevalence of EGFR and KRAS mutations and their correlation with clinical variables in Korean patients with adenocarcinoma of the lung. Formalin-fixed adenocarcinoma specimens from 104 randomly selected patients diagnosed at Kosin University Gospel Hospital from October 1996 to January 2005 were used for the study.

RESULTS:

We found a high prevalence of EGFR mutations and a low prevalence of KRAS mutations. EGFR mutations were present in 24% (25 of 104) of the samples: one mutation in exon 18, 13 in exon 19, one in exon 20, and 10 in exon 21. The presence of an EGFR mutation was not associated with gender, smoking history, histological grade, age, bronchioalveolar components, or cancer stage in patients with adenocarcinoma of the lung.

CONCLUSIONS:

Mutations of KRAS were present in 9.6% (9 of 94) of the samples: eight in codon 12 and one in codon 13. EGFR mutations were never found in tumors with KRAS mutations, suggesting a mutually exclusive relationship.

PMID:
19270482
[PubMed - indexed for MEDLINE]
PMCID:
PMC2687655
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Publishing M2Community Icon for PubMed Central
    Loading ...
    Write to the Help Desk